Background Development of in vivo biomarkers has shifted the diagnosis of Alzheimer's
disease (AD) from the later dementia stages of disease towards the earlier stages and has …

Alzheimer's disease (AD) is a progressive, neurodegenerative disorder that affects memory,
thinking, behavior, and other cognitive functions. Although there is no cure, detecting AD …

Brain imaging techniques using PET improve our understanding of the different AD-related
pathologies and their relationship with each other along the course of disease. With more …

Background Alzheimer's disease (AD) cerebrospinal fluid (CSF) core biomarkers (Aβ42/40
ratio, p-tau, and t-tau) provide high diagnostic accuracy, even at the earliest stage of …

Background Despite the high sensitivity of cerebrospinal fluid (CSF) amyloid beta (Aβ) 42 to
detect amyloid pathology, the Aβ42/Aβ40 ratio (amyR) better estimates amyloid load, with …

ABSTRACT Objectives: Type 2 diabetes (T2D) is a metabolic disease of major public health
concern. It impacts peripheral tissues and the central nervous system, leading to systemic …

Magnetic resonance imaging (MRI) plays a significant role in the routine imaging workflow,
providing both anatomical and functional information. 19F MRI is an evolving imaging …

Antiamyloid therapies for Alzheimer disease recently entered clinical practice, making
imaging biomarkers for Alzheimer disease even more relevant to guiding patient …

Alzheimer's disease (AD) is one of the most common neurodegenerative diseases
worldwide. The occult nature of the onset and the uncertainty of the etiology largely impede …

Alzheimer's disease (AD) is the most common dementia worldwide. The exact etiology of AD
is unclear as yet, and no effective treatments are currently available, making AD a …